Aisha Al-Khinji

Dr. Aisha Al-Khinji

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2018 in Current Hematologic Malignancy Reports
Verified
Journal Article
Closed access
PDF file
Waseem LoneWaseem Lone
Waseem Lone
AAAisha Al-Khinji
Aisha Al-Khinji
JUJayadev Manikkam Umakanthan
Jayadev Manikkam Umakanthan
JIJaveed Iqbal
Javeed Iqbal

16 November 2024 in American Journal of Hematology
Verified
Journal Article
Open access
Waseem LoneWaseem Lone
Waseem Lone
ABAlyssa Bouska
Alyssa Bouska
THTyler A. Herek
Tyler A. Herek
CACatalina Amador
Catalina Amador
JSJoo Song
Joo Song
JIJaveed Iqbal
Javeed Iqbal
High‐grade B‐cell lymphoma not otherwise specified (HGBCL, NOS) has overlapping morphological and genetic features with diffuse large B‐cell lymphoma (DLBCL) and Burkitt lymphoma (BL), leading to uncertainty in its diagnosis and clinical management. Using functional genomic approaches, we previously characterized HGBCL and NOS, that demonstrate gene expression profiling (GEP), and genetic signatures similar to BL. Herein, we characterize distinct HGBCL, NOS, cohort ( n = 55) in adults ( n = 45) and in children ( n = 10), and compared the GEP, genomic DNA copy number (CN), and mutational spectrum with de novo DLBCL ( n = 85) and BL ( n = 52). This subgroup, representing ~60% of HGBCL, NOS, lack gene‐expression signature of BL and double hit/dark zone lymphoma, but express DLBCL like signatures and are characterized by either GCB‐ or ABC‐like mRNA signatures and exhibit higher genomic complexity, similar to de novo DLBCL, and show alteration in genes regulating B‐cell activation ( CD79B , MYD88 , PRDM1 , TBLIXR1 , CARD11 ), epigenome ( KMT2D , TET2 ) and cell cycle transition ( TP53 , ASPM ). However, recurrent mutations in genes often mutated in BL (DDX3X, GNA13, CCND3), but rare in DLBCL, are also present in HGBCL‐NOS, highlighting genetic heterogeneity. Consistent with mutation spectrum, frequent genomic CN alterations in genes regulating B‐cell activation (del‐ PRDM1 , gain‐ BCL6 , ‐ REL , ‐ STAT3 ) and cell cycle regulators (del‐ TP53 , del‐ CDKN2A , del‐ RB1 , gain‐ CCND3 ) were observed. Pediatric cases showed GCB‐DLBCL‐like mRNA signatures, but also featured hallmark mutations of pediatric BL. Frequent oncogenic PIM1 mutations were present in adult HGBCL, NOS. In vitro analyses with pharmacologic or genetic inhibition of PIM1 expression triggered B‐cell activation and NF‐κB‐induced apoptosis, suggesting that PIM1 is a rational therapeutic target.

8 August 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
AAAisha Al-Khinji
Aisha Al-Khinji
NANoora Al-Korbi
Noora Al-Korbi
SASheikha Al-Kuwari
Sheikha Al-Kuwari
AAAbdullatif Al-Hor
Abdullatif Al-Hor
DMDhafer Malouche
Dhafer Malouche
Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies, with poor outcomes despite therapeutic advancements. Immune checkpoint inhibitors (ICIs) have transformed cancer care, but their efficacy in PDAC is limited due to the tumor’s immunosuppressive microenvironment.Methods: We systematically reviewed and meta-analyzed clinical outcomes of ICI therapy in PDAC using studies from PubMed, CINAHL, Cochrane Library, and Google Scholar, published up to February 28, 2024. Eligible studies reported objective response rate (ORR), progression-free survival (PFS), or overall survival (OS). Risk of bias was assessed using RoB 2.0 and ROBINS-I. Random-effects models estimated pooled effect sizes.Results: Fifty-four studies (n = 2,364) were included. ORR ranged from 0% to 67%. ICI-based combinations showed a modest ORR benefit (OR = 1.10; 95% CI: 1.02–1.18) and improved OS when combined with chemotherapy (HR = 0.82; 95% CI: 0.78–0.87). However, ICIs plus radiotherapy were associated with increased mortality (HR = 1.18; 95% CI: 1.04–1.34). PFS improved in select subgroups, particularly in patients with high tumor mutational burden or mismatch repair deficiency.Conclusion: ICIs combined with chemotherapy may modestly improve survival in PDAC. Outcomes remain heterogeneous and limited, underscoring the need for better biomarker-driven patient selection and more effective combination strategies.

10 July 2005 in International Journal of Cardiology
Verified
Journal Article
Closed access
PDF file
HHHadi A.R. Hadi
Hadi A.R. Hadi
JSJassim Al Suwaidi
Jassim Al Suwaidi
ABA. Bener
A. Bener
AAAisha Al-Khinji
Aisha Al-Khinji
HBH.A. Al Binali
H.A. Al Binali

9 April 2015 in Transfusion
Verified
Journal Article
Closed access
PDF file
AAAisha Al-Khinji
Aisha Al-Khinji
MLMichael Linenberger
Michael Linenberger

1 November 2025 in Medical Sciences
Verified
Journal Article
Open access
PDF file
HAHissa Al-Kuwari
Hissa Al-Kuwari
BABelqes Khalil Alshami
Belqes Khalil Alshami
AAAisha Al-Khinji
Aisha Al-Khinji
AHAdnan Haider
Adnan Haider
MAMuhammad Arsalan
Muhammad Arsalan
Background: Renal Cell Carcinoma (RCC) is the most common type of kidney cancer and requires accurate histopathological grading for effective prognosis and treatment planning. However, manual grading is time-consuming, subjective, and susceptible to inter-observer variability. Objective: This study proposes EAT-Net (Efficient Attention Transformer Network), a dual-stream deep learning model designed to automate and enhance RCC grade classification from histopathological images. Method: EAT-Net integrates EfficientNetB0 for local feature extraction and a Vision Transformer (ViT) stream for capturing global contextual dependencies. The architecture incorporates Squeeze-and-Excitation (SE) modules to recalibrate feature maps, improving focus on informative regions. The model was trained and evaluated on two publicly available datasets, KMC-RENAL and RCCG-Net. Standard preprocessing was applied, and the model’s performance was assessed using accuracy, precision, recall, and F1-score. Results: EAT-Net achieved superior results compared to state-of-the-art models, with an accuracy of 92.25%, precision of 92.15%, recall of 92.12%, and F1-score of 92.25%. Ablation studies demonstrated the complementary value of the EfficientNet and ViT streams. Additionally, Grad-CAM visualizations confirmed that the model focuses on diagnostically relevant areas, supporting its interpretability and clinical relevance. Conclusion: EAT-Net offers an accurate, and explainable framework for RCC grading. Its lightweight architecture and high performance make it well-suited for clinical deployment in digital pathology workflows.